title: A Bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infections.
abstract: Antiviral agents are an important component in mitigation/containment strategies for pandemic influenza. However, most research for mitigation/containment strategies relies on the antiviral efficacies evaluated from limited data of clinical trials. Which efficacy measures can be reliably estimated from these studies depends on the trial design, the size of the epidemics, and the statistical methods. We propose a Bayesian framework for modeling the influenza transmission dynamics within households. This Bayesian framework takes into account asymptomatic infections and is able to estimate efficacies with respect to protecting against viral infection, infection with clinical disease, and pathogenicity (the probability of disease given infection). We use the method to reanalyze 2 clinical studies of oseltamivir, an influenza antiviral agent, and compare the results with previous analyses. We found significant prophylactic efficacies in reducing the risk of viral infection and infection with disease but no prophylactic efficacy in reducing pathogenicity. We also found significant therapeutic efficacies in reducing pathogenicity and the risk of infection with disease but no therapeutic efficacy in reducing the risk of viral infection in the contacts.
authors.affiliation: Program of Biostatistics and Biomathematics, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. yang@fhcrc.org
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.forename: M Elizabeth
authors.initials: ME
authors.lastname: Halloran
authors.forename: Ira M
authors.initials: IM
authors.lastname: Longini
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001499:Bayes Theorem; D005191:Family Characteristics; D006801:Humans; D007251:Influenza, Human / Q000097:blood / Q000188:drug therapy* / Q000635:transmission; D008390:Markov Chains; D008954:Models, Biological; D009010:Monte Carlo Method; D053139:Oseltamivir / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D053139:Oseltamivir